AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21986722 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 4 mg/ml-min), Irinotecan (340 mg/m2 for patients on EIAEDs, 125 mg/m2 for others), Bevacizumab (10 mg/kg)
Number of subjects: 40
Study 21986722 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin, Irinotecan, Bevacizumab
Number of subjects: 40
Study 21986736 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (35% developed ARDS)
Number of subjects: 648
Study 21986736 — intervention group
Group type: COMPARATOR
Intervention: Men (25% developed ARDS)
Number of subjects: 648
Study 21986736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ARDS (both genders)
Number of subjects: 648
Study 21986736 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinflammatory sex hormone profile (low testosterone and high estradiol)
Number of subjects: 648
Study 21987241 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 150 mg twice daily for 14 days
Number of subjects: 12
Study 21989407 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Cigarette
Number of subjects: 40
Study 21990384 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial salvage index (MSI) ≥ median
Number of subjects: 208
Study 21990384 — intervention group
Group type: COMPARATOR
Intervention: Myocardial salvage index (MSI) < median
Number of subjects: 208
Study 21991891 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids
Number of subjects: 935
Study 21991892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator administration
Number of subjects: 2163
Study 21991892 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2163
Study 21991892 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with emphysema
Number of subjects: 2163
Study 21991892 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bronchodilator reversibility
Number of subjects: 2163
Study 21991892 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 2163
Study 21992630 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilver PTX drug-eluting stent
Number of subjects: 787
Study 21992853 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 6 mg/kg intravenously plus docetaxel 75 mg/m(2) intravenously, every 3 weeks
Number of subjects: 46
Study 21993671 — intervention group
Group type: EXPERIMENTAL
Intervention: VHL(R200W) homozygotes
Number of subjects: 120
Study 21993671 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy therapy in VHL(R200W) homozygotes
Number of subjects: 120
Study 21993671 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ferritin concentration in VHL(R200W) homozygotes
Number of subjects: 120
Study 21993671 — intervention group
Group type: COMPARATOR
Intervention: Controls with normal VHL alleles
Number of subjects: 120
Study 21994418 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT-801 at 0.04 mg/kg
Number of subjects: 26
Study 21994418 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT-801 treatment
Number of subjects: 26
Study 21994964 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention to reduce fat and increase fiber intake during childhood and adolescence
Number of subjects: 230
Study 21994964 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 230
Study 21995267 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-layer bandaging (4LB)
Number of subjects: 424
Study 21995267 — intervention group
Group type: COMPARATOR
Intervention: short-stretch bandaging (SSB)
Number of subjects: 424
Study 21995329 — intervention group
Group type: EXPERIMENTAL
Intervention: Community and hospital-based care management and coordination intervention
Number of subjects: 19
Study 21996385 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital major bleeding (IHMB)
Number of subjects: 3602
Study 21997132 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized adjuvant treatment in controlled clinical trials
Number of subjects: 14611
Study 21997144 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet usage for health/medical information
Number of subjects: 470
Study 21997144 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet usage for children's health/medical information
Number of subjects: 470
Study 21997144 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic correlates of computer ownership
Number of subjects: 470
Study 21997144 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet usage among parents with ≤ a college degree or BMI <25 kg/m(2)
Number of subjects: 470
Study 21997548 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0
Study 21997548 — intervention group
Group type: COMPARATOR
Intervention: Human CT
Number of subjects: 0
Study 21997548 — intervention group
Group type: COMPARATOR
Intervention: Pathologist's assessment
Number of subjects: 0
Study 21997548 — intervention group
Group type: COMPARATOR
Intervention: Automated software quantification
Number of subjects: 0
Study 21997548 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher liver fat content (assessed by MRI) in patients
Number of subjects: 0
Study 21998067 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 21998698 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) vaccine
Number of subjects: 407
Study 21998698 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 407
Study 21998698 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from RTS,S/AS01(E) and control vaccinees
Number of subjects: 407
Study 21999176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled pen for IM IFNβ-1a administration
Number of subjects: 71
Study 21999346 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting therapy (RLAT)
Number of subjects: 532
Study 21999370 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting therapy (RLAT)
Number of subjects: 435
Study 22002488 — intervention group
Group type: EXPERIMENTAL
Intervention: One-unit umbilical cord blood transplantation
Number of subjects: 50
Study 22002488 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-unit umbilical cord blood transplantation
Number of subjects: 50
Study 22002941 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation-promoting dietary supplements (betaine, metafolin, creatine, and vitamin B(12))
Number of subjects: 0
Study 22002941 — intervention group
Group type: COMPARATOR
Intervention: Control group from a previous randomized double-blind trial using folic acid and betaine
Number of subjects: 0
Study 22003071 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 0
Study 22003071 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1) plus placebo
Number of subjects: 0
Study 22003071 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) plus pertuzumab
Number of subjects: 0
Study 22003071 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus a taxane
Number of subjects: 0
Study 22003071 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1) compared with lapatinib plus capecitabine
Number of subjects: 0
Study 22003107 — intervention group
Group type: EXPERIMENTAL
Intervention: CACD patients (n=30)
Number of subjects: 62
Study 22003107 — intervention group
Group type: COMPARATOR
Intervention: Early AMD patients (n=19)
Number of subjects: 62
Study 22003107 — intervention group
Group type: COMPARATOR
Intervention: AMD patients with GA (n=13)
Number of subjects: 62
Study 22003107 — intervention group
Group type: COMPARATOR
Intervention: AMD patients (n=19)
Number of subjects: 62
Study 22003383 — intervention group
Group type: EXPERIMENTAL
Intervention: NMRC-M3V-Ad-PfCA vaccine, 2×10^10 particle units (1×10^10 each construct)
Number of subjects: 12
Study 22003383 — intervention group
Group type: EXPERIMENTAL
Intervention: NMRC-M3V-Ad-PfCA vaccine, 5-fold higher dose (10×10^10 particle units)
Number of subjects: 12
Study 22003383 — intervention group
Group type: EXPERIMENTAL
Intervention: NMRC-M3V-Ad-PfCA vaccine
Number of subjects: 12
Study 22003411 — intervention group
Group type: EXPERIMENTAL
Intervention: NMRC-MV-Ad-PfC vaccine (adenovirus vector encoding CSP), 1 x 10^10 particle units per dose, two doses 16 weeks apart
Number of subjects: 14
Study 22003411 — intervention group
Group type: EXPERIMENTAL
Intervention: NMRC-MV-Ad-PfC vaccine (adenovirus vector encoding CSP)
Number of subjects: 14
Study 22004373 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment by a doctor
Number of subjects: 198
Study 22004373 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 198
Study 22004373 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous healing
Number of subjects: 198
Study 22004373 — intervention group
Group type: COMPARATOR
Intervention: Routine non-selective surgical intervention
Number of subjects: 198
Study 22004373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive surveillance and early surgical intervention
Number of subjects: 198
Study 22004880 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 0
Study 22005144 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PCT) with surgery, based mainly on a fluorouracil-platinum doublet or triplet regimen.
Number of subjects: 924
Study 22005144 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery (S) without perioperative chemotherapy.
Number of subjects: 924
Study 22005144 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy after surgery in the S group.
Number of subjects: 924
Study 22005144 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy after surgery in the PCT group.
Number of subjects: 924
Study 22005144 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT as a treatment.
Number of subjects: 924
Study 22005150 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy (TT)
Number of subjects: 8032
Study 22005150 — intervention group
Group type: COMPARATOR
Intervention: Bilateral subtotal thyroidectomy (BST)
Number of subjects: 8032
Study 22005184 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater RRV(food)
Number of subjects: 273
Study 22005184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary disinhibition
Number of subjects: 273
Study 22005184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restraint
Number of subjects: 273
Study 22005184 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV(food)
Number of subjects: 273
Study 22005184 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors
Number of subjects: 273
Study 22005709 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing of maternal plasma DNA
Number of subjects: 4664
Study 22005912 — intervention group
Group type: COMPARATOR
Intervention: Nasal brushings from children with dust mite-allergic rhinitis
Number of subjects: 0
Study 22005912 — intervention group
Group type: COMPARATOR
Intervention: Nasal brushings from children with controlled or uncontrolled asthma
Number of subjects: 0
Study 22006113 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 15
Study 22006233 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of autologous platelet-rich fibrin matrix (PRFM) into the deep dermis and subdermis of the skin.
Number of subjects: 4
Study 22007612 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (cilostazol + dual antiplatelet therapy)
Number of subjects: 127
Study 22008340 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rThrombin applied as a hemostatic aid during surgical procedure (day 1)
Number of subjects: 30
Study 22008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker light stimulation in POAG patients (n=47)
Number of subjects: 149
Study 22008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker light stimulation in OHT patients (n=46)
Number of subjects: 149
Study 22008947 — intervention group
Group type: COMPARATOR
Intervention: Flicker light stimulation in healthy controls (n=56)
Number of subjects: 149
Study 22009536 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyl hydrazones
Number of subjects: 0
Study 22009536 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron chelators (desferrioxamine, deferasirox, ciclopirox olamine)
Number of subjects: 0
Study 22009536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine
Number of subjects: 0
Study 22011297 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg-negativity
Number of subjects: 145
Study 22011297 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha fetoprotein (AFP) level
Number of subjects: 145
Study 22011297 — intervention group
Group type: COMPARATOR
Intervention: Ablation method
Number of subjects: 145
Study 22011297 — intervention group
Group type: COMPARATOR
Intervention: Serum HBV DNA titers
Number of subjects: 145
Study 22011412 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood (UCB) infusion
Number of subjects: 24
Study 22011459 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT after one cycle of neoadjuvant chemotherapy
Number of subjects: 78
Study 22011459 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 78
Study 22011635 — intervention group
Group type: EXPERIMENTAL
Intervention: SPOC questionnaire scores at 6 weeks postsurgery
Number of subjects: 359
Study 22012004 — intervention group
Group type: EXPERIMENTAL
Intervention: Genexol-PM 240 mg/m(2) intravenously over 3 h every 3 weeks, with intra-patient dose escalation to 300 mg/m(2) allowed if no pre-specified toxicities were observed.
Number of subjects: 37
Study 22012178 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% propofol emulsion
Number of subjects: 0
Study 22012846 — intervention group
Group type: EXPERIMENTAL
Intervention: Right knee pain only (n=42)
Number of subjects: 126
Study 22012846 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral knee pain (n=42)
Number of subjects: 126
Study 22012846 — intervention group
Group type: COMPARATOR
Intervention: No knee pain (n=42)
Number of subjects: 126
Study 22013821 — intervention group
Group type: EXPERIMENTAL
Intervention: E-prescribing system with clinical decision support
Number of subjects: 21
Study 22013821 — intervention group
Group type: COMPARATOR
Intervention: Paper-based prescriptions (control group)
Number of subjects: 21
Study 22014006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib and metronomic oral cyclophosphamide
Number of subjects: 0
Study 22015991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib dose escalation to 600 mg BID through cycle 2
Number of subjects: 50
Study 22015991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib dose re-escalation to 400 mg BID through cycle 3
Number of subjects: 50
Study 22015991 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of cycle 1 without dose modification or discontinuing treatment
Number of subjects: 50
Study 22015991 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary dose escalation through cycle 2
Number of subjects: 50
Study 22015991 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for escalation failure
Number of subjects: 50
Study 22015991 — intervention group
Group type: EXPERIMENTAL
Intervention: Common grade 3+ adverse events
Number of subjects: 50
Study 22016484 — intervention group
Group type: EXPERIMENTAL
Intervention: Feno measurement pretreatment
Number of subjects: 60
Study 22016484 — intervention group
Group type: EXPERIMENTAL
Intervention: Feno measurement posttreatment
Number of subjects: 60
Study 22016484 — intervention group
Group type: EXPERIMENTAL
Intervention: Feno cut-off value
Number of subjects: 60
Study 22016786 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplant recipients
Number of subjects: 40
Study 22016786 — intervention group
Group type: COMPARATOR
Intervention: Kidney transplant recipients (control)
Number of subjects: 40
Study 22016786 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 22018074 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin D supplementation
Number of subjects: 0
Study 22018679 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg once daily)
Number of subjects: 0
Study 22018679 — intervention group
Group type: COMPARATOR
Intervention: Exenatide (10 μg BID)
Number of subjects: 0
Study 22018706 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 5-line raster and high-definition (HD) 5-line raster scan modes
Number of subjects: 46
Study 22018706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical HD scans
Number of subjects: 46
Study 22018707 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal hysteresis (CH)
Number of subjects: 191
Study 22018707 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal resistance factor (CRF)
Number of subjects: 191
Study 22019221 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller arteriole-to-venule ratio (AVR)
Number of subjects: 1250
Study 22019221 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller AVR
Number of subjects: 1250
Study 22019225 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Retinal Artery Equivalent (CRAE)
Number of subjects: 1250
Study 22019225 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Retinal Vein Equivalent (CRVE)
Number of subjects: 1250
Study 22019225 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriole-to-Venule Ratio (AVR)
Number of subjects: 1250
Study 22019547 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAS-Cog
Number of subjects: 181
Study 22020850 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite soccer training
Number of subjects: 467
Study 22021369 — intervention group
Group type: EXPERIMENTAL
Intervention: Older RBC transfusion (stored for 40-42 days)
Number of subjects: 14
Study 22021722 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and Clavulanic Acid (antibiotic therapy)
Number of subjects: 0
Study 22021757 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga respiratory exercises (Bhastrika)
Number of subjects: 76
Study 22021757 — intervention group
Group type: COMPARATOR
Intervention: Stretching (control)
Number of subjects: 76
Study 22021780 — intervention group
Group type: EXPERIMENTAL
Intervention: Early closure of temporary ileostomy (EASY)
Number of subjects: 200
Study 22021780 — intervention group
Group type: COMPARATOR
Intervention: Late reversal of temporary ileostomy (standard procedure)
Number of subjects: 200
Study 22021788 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycaemic control (intravenous, then subcutaneous insulin to control blood glucose to 4.4-6.5 mmol/l)
Number of subjects: 20
Study 22021788 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycaemic control
Number of subjects: 20
Study 22021870 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Physical Therapy (MPT) - 6 sessions
Number of subjects: 104
Study 22021870 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid Injections (CSI) - 1 to 3 sessions
Number of subjects: 104
Study 22021873 — intervention group
Group type: EXPERIMENTAL
Intervention: Viusid (three oral sachets daily, n=50)
Number of subjects: 100
Study 22021883 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U Dysport (botulinum toxin A)
Number of subjects: 516
Study 22021885 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 h of on-site Road Tour training
Number of subjects: 681
Study 22021885 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 h of on-site Road Tour training with 4 h of booster training at 11 months postrandomisation
Number of subjects: 681
Study 22021885 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 h of at-home Road Tour training using the participant's personal computer
Number of subjects: 681
Study 22021885 — intervention group
Group type: COMPARATOR
Intervention: 10 h of on-site attention control using computerised crossword puzzles (Boatload of Crosswords)
Number of subjects: 681
Study 22022345 — intervention group
Group type: EXPERIMENTAL
Intervention: ¡Viva Bien!
Number of subjects: 280
Study 22022345 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study 22022448 — intervention group
Group type: COMPARATOR
Intervention: RTS,S malaria vaccine
Number of subjects: 0
Study 22023158 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm pacing (electrical stimulation)
Number of subjects: 18
Study 22023777 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine sTREM-1
Number of subjects: 104
Study 22023777 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine sTREM-1, SCr, BUN
Number of subjects: 104
Study 22024527 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR) resistance measured by Monogram weighted score (WS) and DUET WS.
Number of subjects: 225
Study 22024527 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA ≥ 4 log₁₀ copies/ml at failure.
Number of subjects: 225
Study 22024527 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) resistance-associated mutations (RAMs).
Number of subjects: 225
Study 22024601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker (PM) intervention
Number of subjects: 481
Study 22025149 — intervention group
Group type: EXPERIMENTAL
Intervention: R1507 9 mg/kg intravenously once a week
Number of subjects: 115
Study 22025149 — intervention group
Group type: EXPERIMENTAL
Intervention: R1507 27 mg/kg intravenously every three weeks
Number of subjects: 115
Study 22025149 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 115
Study 22025151 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; external-beam radiation therapy (EBRT) 5 days a week at 1.8 Gy/d for 25 fractions
Number of subjects: 93
Study 22025151 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with oxaliplatin, PI-FU, and EBRT
Number of subjects: 93
Study 22025154 — intervention group
Group type: EXPERIMENTAL
Intervention: Figitumumab at 30 mg/kg intravenously every 4 weeks for a median of 2 cycles (range, 1 to 16)
Number of subjects: 107
Study 22025154 — intervention group
Group type: EXPERIMENTAL
Intervention: Figitumumab at 30 mg/kg with baseline free IGF-1 ≥ 0.65 ng/mL
Number of subjects: 107
Study 22025154 — intervention group
Group type: EXPERIMENTAL
Intervention: Figitumumab at 30 mg/kg with pretreatment circulating free IGF-1 lower than 0.65 ng/mL
Number of subjects: 107